Covid: mixed vaccines, including Moderna and Novavax in the Gb studio

London, April 14 (beraking latest news Salute / Dpa) – The anti-Covid vaccines of the American companies Moderna and Novavax will enter the British study ‘Com-Cov’ which is evaluating the possibility of safely ‘mixing’ the products of AstraZeneca / Oxford and Pfizer / BioNTech, by giving the booster with a different vaccine than that used for the first dose. This was announced by scientists from the University of Oxford who lead the research, which began last February.

The scholars are recruiting adults in their 50s or over 50s who have received a first dose of the Covid vaccine in the past 8-12 weeks, and will now enroll an additional 1,050 participants. The goal is “to assess whether the available Covid-19 vaccines” that provide a double dose scheme “can be used in a more flexible way”, explains Matthew Snape, head of the trial.

In this new part of the trial, volunteers who have received a first dose of AstraZeneca / Oxford or Pfizer / BioNTech vaccine will be randomly given the same product or a dose of Moderna or Novavax at the booster stage. The results of the first phase of the trial, on the AstraZeneca and Pfizer vaccines, are expected at the end of this month or in May. The results of the second part of the study, involving Moderna and Novavax, are expected to arrive in July.